Literature DB >> 2009153

Converting enzyme inhibitors and renal function in essential and renovascular hypertension.

A Mimran1, J Ribstein, G DuCailar.   

Abstract

Converting enzyme inhibitors (CEI) are useful in the treatment of hypertension. However, acute renal deterioration may occur in some conditions in association with the crucial role of angiotensin in the regulation of glomerular filtration rate (GFR), such as volume depletion, severe stenosis of both renal arteries, and stenosis of a single functioning kidney. CEI-induced acute renal failure can develop in the absence of a fall in systemic pressure, is facilitated by prior sodium depletion, and is reversible upon discontinuation of treatment. In a personal study conducted in 28 patients with CEI-induced renal dysfunction (reversible after discontinuation of CEI), the incidence of stenosis of large renal vessels was 61%, whereas 39% of these subjects had no significant renal artery abnormalities. Although the occurrence of such a complication is not a convincingly accurate predictor of the existence of renovascular hypertension, angiographic detection of renal artery stenosis (bilateral or on a single-functioning kidney) may be justified in some of these patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009153     DOI: 10.1093/ajh/4.1.7s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

Review 1.  Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function.

Authors:  N D Sturrock; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 2.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Blockade of the Renin-Angiotensin System and the Risk of Acute Kidney Injury.

Authors:  Michel Burnier
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-04-14       Impact factor: 3.738

Review 4.  Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.

Authors:  Christina Antza; Stella Stabouli; Vasilios Kotsis
Journal:  Vasc Health Risk Manag       Date:  2016-11-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.